Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile by Lutgens, Esther et al.
Article
The Rockefeller University Press  $30.00
J. Exp. Med. Vol. 207 No. 2  391-404
www.jem.org/cgi/doi/10.1084/jem.20091293
391
Atherosclerosis is a chronic inflammatory disease 
of the large arteries that involves multiple immuno­
logical processes (Hansson, 2005; Weber et al., 
2008). During the progression of atherosclerosis, 
ongoing activation of the immune system causes 
continuous  recruitment  of  inflammatory  cells 
into the plaque and degradation of its extracellular 
matrix. This creates a so­called vulnerable plaque, 
which is prone to rupture and therefore likely to 
cause acute complications such as myocardial in­
farction or stroke (Virmani et al., 2000).
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The CD40–CD40 ligand (CD40L) signaling axis plays an important role in immunological 
pathways. Consequently, this dyad is involved in chronic inflammatory diseases, including 
atherosclerosis. Inhibition of CD40L in apolipoprotein E (Apoe)–deficient (Apoe/) mice 
not only reduced atherosclerosis but also conferred a clinically favorable plaque phenotype 
that was low in inflammation and high in fibrosis. Blockade of CD40L may not be thera-
peutically feasible, as long-term inhibition will compromise systemic immune responses. 
Conceivably, more targeted intervention strategies in CD40 signaling will have less deleteri-
ous side effects. We report that deficiency in hematopoietic CD40 reduces atherosclerosis 
and induces features of plaque stability. To elucidate the role of CD40–tumor necrosis 
factor receptor-associated factor (TRAF) signaling in atherosclerosis, we examined disease 
progression in mice deficient in CD40 and its associated signaling intermediates. Absence of 
CD40-TRAF6 but not CD40-TRAF2/3/5 signaling abolishes atherosclerosis and confers 
plaque fibrosis in Apoe/ mice. Mice with defective CD40-TRAF6 signaling display a 
reduced blood count of Ly6Chigh monocytes, an impaired recruitment of Ly6C+ monocytes to 
the arterial wall, and polarization of macrophages toward an antiinflammatory regulatory 
M2 signature. These data unveil a role for CD40–TRAF6, but not CD40–TRAF2/3/5, inter-
actions in atherosclerosis and establish that targeting specific components of the CD40–
CD40L pathway harbors the potential to achieve therapeutic effects in atherosclerosis.
© 2010 Lutgens et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the 
publication date (see http://www.jem.org/misc/terms.shtml). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike  3.0  Unported  license,  as  described  at  http://creativecommons.org/licenses/ 
by-nc-sa/3.0/).
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points, as well as in the thoraco­abdominal aorta (Fig. 1 a). 
This was associated with a less inflammatory and more fi­
brotic plaque quality, as reflected by the low amount of thin 
fibrous cap atheromata (Virmani et al., 2000) that developed   
in absence of CD40 (Fig. S1 a). The absence of CD40 reduced 
the lipid core size (ApoE/, 35.4% vs. CD40/ApoE/, 
23.3%; P < 0.05), the number of plaque macrophages, and 
the content of CD45+ cells and CD3+ T lymphocytes (Figs. 1,   
b and c). The number of Foxp3+ regulatory T cells in plaque 
or adventitia was unaffected (Fig. S1, b and c). The numbers 
of cleaved caspase 3+ (apoptotic) cells (Fig. S1 d), as well as the 
degree of iron or fibrin deposition in the plaque (not depicted),   
were unaffected.
Besides the decrease in inflammatory cell content, plaques 
of CD40/Apoe/ mice had a more fibrotic appearance. 
The content of –smooth muscle actin (SMA; ­SMA+ cells; 
Fig. 2 a) and collagen (Fig. 2 b) was significantly increased. 
Bright­field polarization microscopy revealed that in the ab­
sence of CD40, the color distribution of the collagen devi­
ated  toward  the  red  spectrum,  indicating  larger  collagen 
fibrils (MacKenna and Omens, 1996). Concordant with these 
findings, we found an increase in the amount of collagen I 
and III in the plaque (Fig. 2, d and e).
Recent studies have identified the involvement of various 
matrix metalloproteinases in atherosclerotic lesion formation 
and their contribution to fibrous cap thinning by degrading 
extracellular matrix (Hansson and Libby, 2006). Interestingly, 
MMP­2 and MMP­9 expression was decreased in the plaques 
of CD40/Apoe/ mice (Fig. S2, a and b). To confirm an 
impairment of proteolytic activity and effects of tissue inhibi­
tor of metalloproteinase (TIMP) 1, we measured gelatinase 
activity  and  TIMP­1  messenger  RNA  (mRNA)  levels  in 
macrophages stimulated with the CD40­clustering antibody 
FGK45.  We  found  that  gelatinase  activity  was  decreased   
(Fig. S2 c), whereas TIMP­1 levels were increased in CD40­
deficient macrophages (Fig. S2 d).
Leukocyte CD40 deficiency reduces atherosclerosis  
and impairs macrophage migration
To  unequivocally  establish  the  involvement  of  leukocyte 
versus nonleukocyte CD40 in atherosclerosis, we reconsti­
tuted lethally irradiated Ldlr/ mice with CD40/ or WT 
BM and fed the mice with a high­fat diet for 24 wk. Body 
The CD40–CD40 ligand (CD40L) dyad, a costimulatory 
receptor­ligand pair, plays a crucial role in enhancing immune 
responses and inflammation and contributes to a plethora of 
chronic inflammatory diseases, for example, colitis, arthritis, al­
lergic encephalitis, and multiple sclerosis (Durie et al., 1993; 
Gerritse et al., 1996; Lutgens et al., 2007; Vowinkel et al., 
2007).  Disruption  of  the  CD40L  gene  in  apolipoprotein  E 
(Apoe)/ mice abrogated atherosclerosis and caused a plaque 
phenotype with only few inflammatory cells and a high per­
centage of extracellular matrix (Lutgens et al., 1999), which is 
reminiscent of a clinically favorable stable atherosclerotic plaque 
in humans (Virmani et al., 2000). This phenotype was copied 
when Apoe/ mice with initial plaques or established athero­
mata were treated with a blocking anti­CD40L antibody (Mach 
et al., 1998; Lutgens et al., 2000; Schönbeck et al., 2000).
In principle, these findings render targeting of CD40L a 
promising strategy to reduce atherosclerosis and to stabilize 
atherosclerotic plaques. Unfortunately, clinical trials using an 
anti­CD40L antibody have been omitted as a result of throm­
boembolic complications, particularly because CD40L is pres­
ent on platelets and can interact with the integrin IIb3 in 
platelets (Kawai et al., 2000; André et al., 2002).
Antagonizing CD40, the receptor for CD40L, or its sig­
naling intermediates would be an alternative approach for 
treating human atherosclerosis. However, information on the 
effects  of  CD40  and  CD40­associated  signal  transduction 
pathways in atherosclerosis is scarce. It has been shown that 
low-density lipoprotein receptor (Ldlr)–deficient (Ldlr/) mice 
lacking the CD40 gene do not develop smaller atheroscle­
rotic lesions than control Ldlr/ mice (Zirlik et al., 2007b), 
although a proatherogenic role for endothelial CD40–TNF 
receptor­associated factor (TRAF) 1, 2, 3, 5, and 6 signaling 
in atherosclerosis has been claimed (Zirlik et al., 2007a). Using 
mice carrying a CD40 transgene with targeted mutations at 
the CD40­TRAF6 recognition site, we found that CD40­
TRAF6 signaling is specifically required for arterial neointima 
formation (Donners et al., 2008).
In the present study, we tried to elucidate the role of 
CD40 and its associated signaling intermediates, the TRAFs, 
in primary atherosclerosis in vivo in detail. We found that 
CD40/Apoe/  mice  had  a  reduction  in  atherosclerosis 
and developed a stable atherosclerotic plaque phenotype. BM   
transplantation of CD40/ BM into Ldlr/ mice revealed 
that hematopoietic CD40 was responsible for the observed 
phenotype.  Surprisingly,  when  CD40–TRAF6,  but  not 
CD40–TRAF2/3/5, interactions were defective, atheroscle­
rosis was completely abrogated.
RESULTS
CD40 deficiency reduces atherosclerosis
We generated CD40/Apoe/ mice and analyzed the extent 
and phenotype of atherosclerosis at 26 wk of age on a normal 
chow diet. Body weight, as well as cholesterol content or plasma 
sCD40L levels did not differ between the groups (Table I).
As in CD40L/Apoe/ mice, deficincy of CD40 reduced   
the atherosclerotic plaque area in the aortic arch and its branch 
Table I.  Body weights, plasma cholesterol levels, and sCD40L 
serum levels did not differ between the genotypes (P > 0.05)
Genotype Body weight Cholesterol sCD40L
g mg/dl ng/ml
Apoe/  28.7 ± 0.8 275 ± 16 4.0 ± 0.8
CD40/Apoe/  29.2 ± 0.8 299 ± 24 5.6 ± 1.6
CD40-Twt  26.1 ± 0.8 328 ± 26 3.3 ± 1.0
CD40-T2/3/5/ 24.9 ± 0.7 297 ± 33 5.0 ± 2.6
CD40-T6/ 24.8 ± 0.8 283 ± 12 2.9 ± 0.5
CD40-T2/3/5/6/ 28.9 ± 0.7 330 ± 36 5.3 ± 1.9JEM VOL. 207, February 15, 2010 
Article
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Figure 1.  Role of CD40 in atherosclerosis. (a–c) Apoe/ mice (n = 19) were fed a normal chow diet for 26 wk and were compared with CD40/ 
Apoe/ (n = 16). Sections of the aortic arch and its main branch points (brachiocephalic artery, right subclavian artery, right carotid artery, left carotid 
artery, and left subclavian artery) were stained with hematoxylin and eosin (HE; representative sections in a, bottom) to analyze the extent of atheroscle-
rosis (plaque area; a, top left: plaque area aortic arch and branch points; a, top right: en face staining thoraco-abdominal aorta; bars, 2 mm; horizontal 
bars represent mean) and plaque phenotype (b and c). (b) Macrophage infiltration was expressed as the absolute number of Mac3+ cells per plaque (bars, 
100 µm). (c) CD45 and CD3 content were expressed as the percentage of CD3+ or CD45+ cells of all plaque cells (arrows indicate CD45+ cells; bars, 50 µm). 
Error bars represent mean ± SEM. *, P < 0.05.394 CD40-TRAF6 signaling in atherosclerosis | Lutgens et al.
Figure 2.  Deficiency of CD40 induces plaque fibrosis. Sections of the aortic arch and its main branch points (brachiocephalic artery, right and left 
subclavian artery, and right and left carotid artery) of Apoe/ mice (n = 19) and CD40/Apoe/ (n = 16) mice fed a normal chow diet for 26 wk were 
stained for -SMA to detect the content of SMCs (a, representative sections on the left; bars, 50 µm), which was quantified as the percentage of -SMA–
positive plaque area (a, right). (b and c) Consecutive sections were stained with Sirius red to assess the content of collagen in the plaque by light (b) and 
polarized light (c) microscopy (representative sections on the left; bars, 50 µm). In addition, the content of collagen was expressed as the percentage of 
-SMA–positive plaque area (b, right) and the color spectrum obtained using polarization microscopy was analyzed (c, right). (d and e) The content of 
collagen I (d) and collagen III (e) was assessed by immunohistochemistry (representative sections on the left; bars, 100 µm) and expressed as the percent-
age of positively stained plaque area (right). Error bars represent mean ± SEM. *, P < 0.05.JEM VOL. 207, February 15, 2010 
Article
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weights and plasma cholesterol levels did not differ between 
the groups (body weight, 20.1 vs. 19.7 g in Ldlr/; P > 0.05; 
cholesterol, 368 vs. 357 mg/dL Ldlr/). Chimeric Ldlr/ 
mice with CD40/ BM exhibited markedly reduced ath­
erosclerosis in the aortic arch including its branch points and   
in the thoraco­abdominal aorta (Fig. 3 a). Similar to CD40/ 
Apoe/ mice, atherosclerotic plaques of chimeric CD40/ 
Ldlr/ mice contained less Mac3+ macrophages (Fig. 3 b).   
In culture, CD40/ macrophages showed an impaired mi­
gration toward CCL2 (Fig. 3 c). Moreover, the percentage of 
CD45+ cells and CD3+ T lymphocytes in the plaque was de­
creased (Fig. 3 e). In accordance with this antiinflammatory 
profile in the plaque, absence of CD40 strongly decreased   
the expression of IB in FGK45­stimulated macrophages 
(Fig. 3 d), suggesting that the phenotypic effects are mediated by 
NF­B signaling. Total collagen content (Fig. 3 f) and smooth 
muscle cell (SMC) content (Fig. 3 f) were increased in the 
plaque in absence of CD40. These data reveal a crucial role for 
leukocyte­dependent CD40 signaling in atherosclerosis.
Deficiency of CD40 polarizes macrophages toward  
an M2 phenotype
Stimulation of CD40 with the clustering antibody FGK45 in 
BM­derived macrophages resulted in a significant induction of 
the proinflammatory cytokines IL­12, iNOS (Fig. 4 a), and 
CCL­2 (not depicted) and a significant reduction of IL­10 
(Fig. 4 c) in WT but not in CD40/ macrophages, indicating 
that absence of CD40 polarizes macrophages toward an M2 
phenotype (Martinez et al., 2009). To further differentiate the 
M2 subset into wound­healing and regulatory macrophages 
(Mosser and Edwards, 2008), real­time PCR analysis for re­
spective markers was performed in FGK45­stimulated BM­
derived  macrophages.  We  observed  that  CD40  deficiency 
significantly reduced the inflammatory M1 markers iNOS and 
IL­12 (Fig. 4 a), only slightly reduced the expression of the 
wound­healing  macrophage  markers  YM­1  and  RELM­, 
and  did  not  affect  the  expression  of  arginase­I,  IGF­1,  or 
DCIR (Fig. 4 b), suggesting that CD40 signaling is essential for 
polarization of macrophages toward the M1 subtype but not 
toward wound­healing macrophages. Moreover, absence of 
CD40 did not result in an increase in collagen 1A1 produc­
tion in these macrophages (Fig. 4 b). In contrast, deficiency of 
CD40 strongly induced the regulatory macrophage marker   
IL­10, whereas SPKH1 expression was not affected (Fig. 4 c), 
indicating that CD40 deletion shifts the macrophage pheno­
type to an antiinflammatory regulatory signature.
CD40 deficiency affects T cell and DC phenotype
To elaborate on the immune phenotyping, we performed 
flow cytometry analysis of blood, spleen, and lymph node cells   
(Fig. S3). Consistent with the atherosclerotic phenotype, anal­
ysis of the different T lymphocyte and DC subsets revealed 
an  antiinflammatory  profile  in  CD40/Apoe/  versus 
Apoe/ mice. Whereas effector memory (CD44highCD62Llow) 
CD4+ and CD8+ T lymphocytes were decreased, naive (CD­
44lowCD62Lhigh) CD4+ and CD8+ T lymphocytes were increased   
(Fig. S3 a). Moreover, CD11c+CD8CD4+ DCs, a popula­
tion associated with antiinflammatory responses, was more 
prominent, whereas CD11c+CD4CD8 and plasmacytoid 
DCs, populations associated with proinflammatory responses, 
were reduced (Fig. S3 b) (Shortman and Liu, 2002).
CD40-TRAF signaling in atherosclerosis
We  next  examined  which  of  the  CD40­associated  signal 
transduction  pathways  was  responsible  for  the  phenotype 
observed in CD40/Apoe/ mice. CD40 has no intrinsic 
signaling ability but requires adaptor molecules, TRAFs, to 
confer signaling. The cytoplasmic tail of CD40 contains three 
binding domains: a proximal domain that binds TRAF6 and 
two distal domains that bind TRAF1, TRAF2, TRAF3, and, 
indirectly,  TRAF5  (Zapata,  2003;  Lu  et  al.,  2007;  Lutgens   
et al., 2007). The separate TRAF binding sites are coupled to 
divergent  signaling  pathways  involving  different  CD40 
downstream modulators and effectors (Lutgens et al., 2007; 
Engel et al., 2009; Lievens et al., 2009), depending on the 
target cell types involved. To unravel the contribution of 
CD40­TRAF2/3/5 versus CD40­TRAF6 signaling in MH­
CII+ cells to atherosclerosis, we used CD40/ mice express­
ing a chimeric CD40 transgene with mutations at the TRAF6 
and/or TRAF2/3/5 binding site under control of the MH­
CII promotor (CD40-T2/3/5/, CD40-T6/, and CD40-
T2/3/5/6/ mice, respectively) or CD40/ mice carrying 
the transgene without mutations (CD40-Twt mice; Ahonen 
et al., 2002; Donners et al., 2008) and backcrossed them with 
Apoe/ mice. At 26 wk of age on a normal chow, atheroscle­
rosis was analyzed in the aortic arch, including its main branch 
points, and the thoraco­abdominal aorta, including the iliac 
artery bifurcation (unpublished data). Body weight, plasma 
cholesterol level, and serum sCD40L level did not differ be­
tween the genotypes (Table I).
CD40-TRAF2/3/5 signaling does not affect atherosclerosis
The atherosclerotic plaque area, the plaque phenotype (Virmani 
et al., 2000), the plaque quality, as evident by the content of   
the lipid core, Mac­3+ cells, CD45+ cells, CD3+ T cells, collagen 
(I and III), SMCs, cleaved caspase 3, and macrophage polarization 
did not differ between CD40-T2/3/5/ and CD40-Twt mice, 
indicating  that  deficiency  in  CD40­TRAF2/3/5  signaling 
does not affect atherosclerosis (Figs. 5 and 6). In fact, CD40-
T2/3/5/ mice displayed even higher numbers of CD4+ cells 
(Fig. S4 a) and CD8+CD44highCD62Llow effector memory T 
lymphocytes in blood, spleen, and/or lymph nodes than CD40-
Twt mice and elevated CD8+ resident DCs (Fig. S3, c and d), a 
subtype which is characterized by increased IL­12 production 
(Shortman and Liu, 2002). This apparently proinflamma­
tory  profile  was  counterbalanced  by  elevated  numbers  of 
CD4+CD25+FoxP3+  regulatory T  lymphocytes  in  blood, 
spleen, and lymph nodes of CD40-T2/3/5/ mice (Fig. S4 b). 
Regulatory T cell function had not changed (Fig. S4 c), and 
because of the balanced effector T cell and regulatory T cell ra­
tio systemic levels of IFN­, IL­6, TNF­, IL­12, or IL­10 
were unaltered (not depicted). Notably, in CD40-T2/3/5/ 396 CD40-TRAF6 signaling in atherosclerosis | Lutgens et al.
Figure 3.  Role of hematopoietic cell–derived CD40 in diet-induced atherosclerosis. (a–f) WT→Ldlr/ chimeras (n = 19) were fed a normal chow 
diet for 26 wk and were compared with CD40/→Ldlr/ BM chimeras (n = 19). Sections of the aortic arch and its main branch points (brachiocephalic 
artery, right and left subclavian artery, and right and left carotid artery) were stained with hematoxylin and eosin and the thoraco-abdominal aorta was 
stained with Sudan IV (representative examples in a, right) to analyze the extent of atherosclerosis (a, left: plaque area in the arch; a, middle: plaque area 
in the thoraco-abdominal aorta; horizontal bars represent mean) and phenotype (b–f). (b) Macrophage infiltration was expressed as the absolute number 
of Mac3+ cells per plaque (bars, 100 µm). (c) Migration of BM-derived macrophages toward CCL2 for 4 h was analyzed in a Transwell migration assay (n = 
6 per group, three independent experiments). (d) Levels of IB in FGK45-stimulated macrophages were determined by real-time PCR (n = 6). (e) CD45 
and CD3 content were expressed as the percentage of CD3+ or CD45+ cells of all plaque cells (arrows indicate CD45+ cells; bars, 50 µm). (f) The content of 
collagen (representative sections on the right; bars, 100 µm) and -SMA was expressed as the percentage of positively stained plaque area. Error bars 
represent mean ± SEM. *, P < 0.05.JEM VOL. 207, February 15, 2010 
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Figure 4.  Deficiency in CD40 induces polarization of macrophages 
toward a regulatory M2 macrophage phenotype. BM-derived macro-
phages of WT and CD40/ mice were cultured, stimulated with 1 µg/ml 
of the CD40-clustering antibody FGK45, and analyzed for expression of 
different M1 (a) and M2 (b, wound-healing macrophages; c, regulatory 
macrophages) subset markers by real-time PCR. n = 6 per group of two 
independent experiments. Error bars represent mean ± SEM. *, P < 0.05.
mice the content of CD4+CD25+FoxP3+ regulatory T lym­
phocytes was also increased in the adventitia underlying the 
plaques but not in the plaque itself (Fig. S4 d).
Inhibition of CD40-TRAF6 signaling abolishes atherosclerosis
In a remarkable contrast, deficiency of CD40­TRAF6 signal­
ing almost completely abolished the development of athero­
sclerosis, as only few intimal xanthomas or fatty­streak lesions 
(classified according to Virmani et al. [2000]) were detectable 
in the aortic arch and its branch points (Fig. 5 a), and no plaques 
were present in the thoraco­abdominal aorta of CD40-T6/ 
mice (Fig. 5 a). This reduction of atherosclerosis was even 
more pronounced than in CD40/Apoe/ mice, likely be­
cause of the effects of residual CD40­TRAF2/3/5 signaling on 
regulatory T lymphocytes. Concomitantly, macrophage, CD45+ 
cell, and CD3+ T lymphocyte infiltration, but also collagen 
(I and III), ­SMA, and MMP­2 and MMP­9 content, were 
substantially reduced in the hardly evolved lesions of CD40-
T6/ mice (Fig. 5, b and c; Fig. 6; and Fig. S5).
The population of peripheral blood Ly6Chigh monocytes 
was significantly declined (Fig. 7 a). Moreover, CD40-T6/ 
macrophages  had  an  impaired  capacity  to  migrate  toward 
CCL2 (Fig. 7 b). Intravital microscopy showed that the adhe­
sion of circulating leukocytes and, in particular, that of Ly6C+ 
monocytes to carotid arteries was significantly impaired in 
CD40-T6/ mice (Fig. 7, c and d).
CD40-TRAF6 deficiency polarizes macrophages  
toward a regulatory M2 phenotype
BM­derived macrophages of CD40-T6/ mice stimulated 
with FGK45 produced less IL­12 and iNOS but increased 
amounts of IL­10 (Fig. 8), indicating that CD40­TRAF6 defi­
ciency  skews  macrophage  polarization  toward  an  antiin­
flammatory M2 phenotype. Further subtyping of the M2 
macrophages into wound­healing and regulatory macro­
phages (Mosser and Edwards, 2008) showed that CD40–TRAF6 
interactions  did  not  affect  the  wound­healing  macrophage 
markers YM­1, RELM­, arginase I, IGF1, or DCIR but 
markedly dampened the M1 polarization response and, rather, 
induced a regulatory macrophage subtype that produces high 
amounts of IL­10. Importantly, the process of monocyte re­
cruitment driven by CD40­TRAF6 was mediated by IL­10, as 
treatment of CD40­T6/ mice with a blocking antibody to 
IL­10 reversed the protective effect on Ly6C+ cell numbers and 
adhesion (Fig. 7 d). The phenotype that occurs in CD40-T6/ 
mice is likely associated with an impaired NF­B signaling   
because IB levels in macrophages were markedly decreased 
(Fig. 8 d). Consistent with findings in CD40­deficient macro­
phages, CD40-T6/ macrophages displayed a reduced gelati­
nolytic activity and increased expression of TIMP­1 (Fig. S5, c 
and d). Flow cytometry analysis further revealed reduced num­
bers of CD4+CD44highCD62Llow promigratory effector mem­
ory T lymphocytes and plasmacytoid DCs (Figs. S3, c and d).
Deficiency of CD40–TRAF2/3/5/6 interactions induces 
plaque fibrosis
It is of note that mice with a combined deficiency in CD40­
TRAF2/3/5/6 binding were characterized by an intermediate 
phenotype, further supporting counter­curing effects of CD40­
TRAF2/3/5 and CD40­TRAF6 signaling in atherosclerosis. 
CD40-T2/3/5/6/ mice showed only a slight reduction in 
atherosclerosis (Fig. 5 a) but displayed features of atheroscle­
rotic plaque stability (Fig. 5 a), with an increased number of fi­
brocalcific plaques containing smaller lipid cores and reduced 
CD45+ cell and CD3+ T lymphocyte infiltrations.
Plaques of CD40-T2/3/5/6/ mice exhibited high lev­
els of collagen (Fig. 6, a–c) and ­SMA–positive SMCs (3.1 ± 
0.7 vs. 5.1 ± 0.9; P < 0.05). Polarized light microscopy on 
Sirius red–stained sections further showed that the majority of 
this collagen consisted of large fibrils, as evident by the high 398 CD40-TRAF6 signaling in atherosclerosis | Lutgens et al.
Figure 5.  Role of CD40-TRAF signaling in atherosclerosis. CD40-Twt (n = 12), CD40-T2/3/5/ (n = 16), CD40-T6/ (n = 19), and CD40-
T2/3/5/6/ (n = 14) were backcrossed to Apoe/ mice and fed a normal chow diet for 26 wk. (a–d) Sections of the aortic arch and its main branch 
points (a; brachiocephalic artery, right subclavian artery, right carotid artery, left carotid artery, and left subclavian artery) were stained with hematoxylin 
and eosin (HE) to analyze the extent of atherosclerosis (plaque area) and plaque phenotype. (a) Plaque area and distribution of morphological plaque 
phenotypes according to the classification by Virmani et al. (2000; top; horizontal bars represent mean). Representative hematoxylin and eosin–stained 
sections in the middle and on the bottom reveal only limited atherosclerosis in absence of CD40-T6 signaling (bars: [middle] 2 mm; [bottom] 100 µm).  
(b–d) CD40-T6/ mice have small atherosclerotic lesions that contain few macrophages (b), CD45+ cells, and CD3+ T cells (c). The level of cleaved caspase 
3 was determined by grading plaque from 0 (no expression) to 3 (high expression; d). Error bars represent mean ± SEM. *, P < 0.05.JEM VOL. 207, February 15, 2010 
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Figure 6.  Role of CD40-TRAF signaling in plaque fibrosis. (a–c) Sirius red–stained sections showed low levels of collagen in the initial plaques of 
CD40-T6/ mice and increased levels in plaques of CD40-T2/3/5/6/ mice (bars, 50 µm). Collagen content was assessed by light (a) and polarized light 
(b) microscopy and expressed as the percentage of Sirius red–stained plaque area (right). In addition, the color spectrum obtained under polarization  
microscopy was analyzed (c). (d and e) The content of collagen I (d) and collagen III (e) was assessed by immunohistochemistry (representative sections  
on the left; bars, 100 µm) and expressed as the percentage of positively stained plaque area (right). Error bars represent mean ± SEM. *, P < 0.05.
percentage of the red fraction (Fig. 8, c and d). In concor­
dance with this finding, plaque levels of collagen I were sig­
nificantly increased, whereas collagen III levels were unaffected 
(Fig. 6, e and f). Moreover, plaque MMP­2 and MMP­9 lev­
els were significantly reduced in CD40-T2/3/5/6/ mice 
(Fig. S5, a and b), indicating a decreased proteolytic activity in 
these  plaques.  Accordingly,  BM­derived  macrophages  of 
CD40-T2/3/5/6/ mice treated with CD40­clustering anti­
body FGK45 displayed reduced gelatinolytic activity and ele­
vated levels of TIMP­1 mRNA (Fig. S5, c–e).
As  in  CD40-T6/  mice,  macrophages  of  CD40-
T2/3/5/6/ mice stimulated with FGK45 exhibited an M2 
macrophage profile with decreased IL­12 production and in­
creased production of IL­10, whereas ly6Chigh monocyte num­
bers and adhesive function were unaffected (Figs. 7 and 8). 
CD40-T2/3/5/6/  mice  shared  increased  CD8+  effector 
memory T lymphocytes with CD40-T2/3/5/ mice and 
decreased plasmacytoid DC numbers with CD40-T6/ mice 
(Fig. S3, c and d). This indicates that some features, namely 
reduced inflammatory monocyte arrest and macrophage po­
larization, are exclusive to CD40-T6/ mice and are not 
compensated for by deficiency of both TRAF binding sites.
DISCUSSION
In this study, we found a clearly divergent action of the two 
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showed reduced numbers and reduced arterial recruitment of 
Ly6Chigh  monocytes,  the  inflammatory  monocyte  subset 
which  dominates  in  hyperlipidemia  (Swirski  et  al.,  2007; 
Tacke et al., 2007), can easily enter the arterial wall, and can 
differentiate  into  intimal  macrophages.  In  parallel,  CD40-
T6/ mice showed a reduction in the classically activated 
M1 macrophage subset producing iNOS and IL­12, which is 
involved in clearing intracellular parasites or tumors and elicit­
ing tissue disruption (Gordon, 2003; Mosser and Edwards, 
2008). Macrophages of CD40-T6/ mice were skewed to­
ward the M2 phenotype and particularly toward the IL­10–
producing regulatory subtype (Mosser and Edwards, 2008). 
Interestingly, the reduced recruitment of Ly6Chigh mono­
cytes in the carotid artery of CD40­T6/ mice could be   
reversed by blocking IL­10, indicating that there could be a 
link between the IL­10–producing macrophage phenotype 
and effects on subsequent monocyte recruitment. Surpris­
ingly, markers of the eponymously termed wound­healing 
macrophages, which contribute to the healing response after 
tissue destruction, were unaltered in the absence of CD40–
TRAF6 interactions, although high levels of plaque fibrosis 
were observed in CD40-T2/3/5/6/ mice. However, the rel­
evance of these data has to be further substantiated and validated 
CD40–TRAF6 interactions in MHCII+ cells nearly abrogated 
atherosclerosis, an effect more marked than CD40 deletion it­
self, whereas deficiency of CD40–TRAF2/3/5 interactions 
did not affect atherosclerosis but, rather, showed a tendency 
to aggravate atherosclerosis. The CD40–TRAF6 interactions 
appeared to be specifically required for the proatherogenic ac­
tivity exerted by cells of the myeloid lineage. Deficiency of 
CD40–TRAF6 interactions limits the subset of Ly6Chigh in­
flammatory monocytes and attenuates their adhesion to and 
infiltration into the arterial wall, thereby abolishing athero­
sclerotic plaque formation. The few monocytes that succeed 
in infiltrating the arterial wall, rather, differentiate into macro­
phages  with  an  antiinflammatory  regulatory  M2  signature, 
thereby preventing plaque inflammation and progression.
In this paper, we provide conclusive evidence for an im­
portant role of CD40–TRAF6 interactions in the recruitment 
and fate of monocytes/macrophages. Diversity and plasticity 
are a hallmark of the monocyte/macrophage lineage, and their 
phenotype strongly depends on their microenvironment and 
the inflammatory signals they perceive (Gordon, 2003; Mosser 
and  Edwards,  2008;  Auffray  et  al.,  2009).  We  found  that 
CD40­TRAF6  signaling  affects  the  homeostasis  of  both 
monocyte and macrophage polarization. CD40­T6/ mice 
Figure 7.  CD40-TRAF signaling affects monocyte homeostasis and recruitment. (a) The percentage of Ly6Chigh monocytes is reduced in the pe-
ripheral blood of CD40-T6/ mice. Horizontal bars represent the mean. (b) Macrophages deficient in CD40-TRAF6 signaling have an impaired capacity to 
migrate toward CCL2 in a Transwell migration assay. (c and d) Accordingly, rhodamine-labeled leukocytes (c) and Ly6C+ monocytes (d) display an impaired 
luminal adhesion to the wall of carotid arteries in absence of CD40–T6 interactions in vivo, which is reversed by pretreatment with a blocking antibody to 
IL-10 (d). Error bars represent mean ± SEM. *, P < 0.05.JEM VOL. 207, February 15, 2010 
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Figure 8.  Deficiency in CD40-TRAF6 interactions induces polarization of macrophages toward a regulatory M2 macrophage phenotype.  
(a–c) BM-derived macrophages of CD40-Twt, CD40-T2/3/5/, CD40-T6/, and CD40-T2/3/5/6/ mice were cultured, stimulated with 1 µg/ml of the 
CD40-clustering antibody FGK45, and analyzed for expression of different M1 (a) and M2 (b, wound-healing macrophages; c, regulatory macrophages) 
subset markers by real-time PCR. n = 6 per group of two independent experiments. (d) The levels of IB in FGK45-stimulated macrophages were  
decreased in BM-derived macrophages of CD40-T6/ and CD40-T2/3/5/6/ mice (n = 6). Error bars represent mean ± SEM. *, P < 0.05.402 CD40-TRAF6 signaling in atherosclerosis | Lutgens et al.
overexpression  prevented  CD40­induced  proinflammatory 
cytokine expression (Urbich et al., 2001).
A clearer picture of the function of CD40–TRAF2/3/5 
interactions has emerged in B cell biology. CD40­TRAF2 
signaling is crucial for germinal center formation, induces 
JNK  activation,  and,  in  particular,  NF­B2  activation 
(Tsukamoto et al., 1999; Au and Yeh, 2007; Vallabhapurapu 
et al., 2008). This is in accordance with our findings that 
IB mRNA expression was not significantly decreased in 
CD40-T2/3/5/  macrophages.  Together  with  CD40–
TRAF5 interactions, which are also required for Ig produc­
tion,  CD40­TRAF2  signaling  up­regulates  costimulatory 
molecules (Au and Yeh, 2007). In contrast, TRAF3 acts as an 
inhibitor  reducing  costimulatory  molecule  expression  and 
IgM production (Bishop and Xie, 2007). In cell types and 
organs other than B cells or lymph nodes, however, most of 
these functions are irrelevant. Consistent with our data, the 
overall effect of CD40­TRAF2/3/5 signaling with regards to 
atherogenesis appears to be balanced.
Our findings may harbor new and interesting therapeutic 
possibilities. The complete inhibition of CD40–CD40L sig­
naling in atherosclerosis is not therapeutically feasible because 
long­term treatment will compromise systemic immune re­
sponses  and  also  entails  thromboembolic  complications. 
Therefore, inhibition of the TRAF6 binding site on CD40, 
using small molecules or an antagonizing CD40 antibody that 
changes the conformation of the CD40­TRAF binding sites, 
may be a suitable alternative. It is conceivable that the protec­
tion by CD40­TRAF6 blockade is conferred by skewing the 
immune response to a more antiinflammatory profile, namely 
through increased production of IL­10 and its effects on miti­
gating the relative propensity, recruitment, and differentiation 
of proinflammatory monocytes. Not only could inhibition of 
the CD40­TRAF6 binding site reduce atherosclerosis more 
effectively than a complete inhibition of CD40 or CD40L by 
avoiding an interference with potentially protective effects by 
remaining CD40­signaling pathways, it may also leave the 
normal functions of these pathways unaffected, and would 
therefore be expected to only cause limited side effects. How­
ever, although our results in the mouse model are promising, 
caution should be applied when extrapolating these experi­
mental data to the human situation. The effects of such selec­
tive targeting strategies will have to be meticulously scrutinized 
before being translated into a clinical setting.
MATERIALS AND METHODS
Animals.  CD40/,  CD40-Twt,  CD40-T2/3/5/,  CD40-T6/,  and 
CD40-T2/3/5/6/ mice (all on a C57Bl6 background; Ahonen et al., 
2002) were backcrossed for seven generations to Apoe/ mice. Ldlr/ mice 
were purchased from The Jackson Laboratory. All study protocols involving 
animal experiments were approved by the Animal Care and Use committee 
of the University of Maastricht and were performed according to official 
rules formulated in the Dutch law on care and use of experimental animals, 
which are highly similar to those of the National Institutes of Health.
Primary  atherosclerosis. CD40/Apoe/ (n = 16), CD40+/+Apoe/  
(n = 19), CD40-Twt (n = 14), CD40-T2/3/5/ (n = 17), CD40-T6/ (n = 26), 
and CD40-T2/3/5/6/ (n = 14) mice were fed a normal chow diet through­
out the experiment.
because the functional role of different monocyte and macro­
phage subsets in atherosclerosis remains to be fully elucidated 
(Mantovani et al., 2009; Swirski et al., 2009). For now, our 
data clearly reveal that a deficiency of CD40–TRAF6 inter­
actions confers an immune­regulatory phenotype in the 
monocyte/macrophage lineage, which reduces atherosclerosis 
and is capable of inducing plaque stability.
In vascular pathobiology, only few data are available on 
the  role  CD40–TRAF6  interactions.  Recently,  CD40–
TRAF6 interactions in MHCII+ cells have also been impli­
cated  in  neointima  formation  in  a  mouse  ligation  model 
(Donners et al., 2008). Moreover, it has been observed that 
stimulation with CD40L induces CD40–TRAF6 interac­
tions in endothelial cells but that their disruption surpris­
ingly results in increased expression of CCL2 (Zirlik et al., 
2007a). More evidence has been gathered regarding the role 
of CD40–TRAF6 interactions in hematopoietic cell types 
including cells of the myeloid lineage. In B cells, effects of 
CD40­TRAF6 signaling comprise germinal center forma­
tion, NF­B activation, IL­6 production, and up­regulation 
of costimulatory molecules (Tsukamoto et al., 1999; Ahonen 
et al., 2002; Hostager, 2007). In monocytes/macrophages, 
CD40–TRAF6  interactions  induce  NF­B  and  ERK   
activation, as well as the production of TNF­ and IL­6 
(Mukundan et al., 2005). In DCs, CD40­TRAF6 signaling 
is required for MHCII surface expression and IL­6 and IL­
12 production (Kobayashi et al., 2003). Differences in the 
effector functions of CD40­TRAF6 signaling between the 
various cell types may be a result of context­specific embed­
ding of downstream pathways.
Our data further show that CD40–TRAF2/3/5 interac­
tions on MHCII+ cells appear to be required for maintaining 
T lymphocyte homeostasis in atherosclerosis. Absence of 
CD40–TRAF2/3/5 interactions increased the numbers of 
CD4+ T cells and promigratory CD8+CD44highCD62Llow ef­
fector memory T lymphocytes, which by itself would likely 
be  sufficient  to  aggravate  atherosclerosis.  However,  the   
increase  in  T  cells  was  compensated  by  an  increase  in 
CD4+CD25+FoxP3+  regulatory  T  lymphocytes,  both  sys­
temically and in the vasculature. This expansion of regulatory 
T cells as an atheroprotective T cell subtype (Ait­Oufella   
et al., 2006) may protect CD40-T2/3/5/ mice against the 
T cell–induced exacerbation of atherosclerosis.
Data on the role of CD40­T2/3/5 signaling in vascular 
biology  are  scarce  and  not  uniform,  as  the  induction  of 
CD40­TRAF2/3/5 signaling yields different outcomes de­
pending on the cell types and pathologies involved. Consis­
tent with the present study, we did not find an effect on 
neointima formation after carotid artery ligation in CD40­
T2/3/5/ mice (Donners et al., 2008). However, TRAF2/ 
and  TRAF5/  endothelial  cells  failed  to  produce  IL­6 
upon  stimulation  with  CD40L,  whereas  CCL2  induction 
was unaffected (Zirlik et al., 2007a). In areas with high shear 
stress,  TRAF3  expression  in  endothelial  cells  covering   
human atherosclerotic plaques is up­regulated and may act as   
a feedback mechanism limiting endothelial activation, as its JEM VOL. 207, February 15, 2010 
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BM transplantation. Ldlr/ mice (n = 44) were maintained in filter­top 
cages and given water containing 60,000 U/liter polymyxin B sulfate (Invit­
rogen) and 100 mg/liter neomycin (Invitrogen) from 1 wk before BM trans­
plantation  until  4  wk  thereafter.  Mice  were  lethally  irradiated  (10  Gy,   
0.5 Gy/min; MU 15F/225 kV; Philips) and i.v. injected with 107 BM cells 
from CD40/ mice or CD40+/+ mice. 4 wk after transplantation, mice 
were fed a 1.25% cholesterol diet for 24 wk.
Atherosclerosis experiments. Mice were sacrificed and the arterial tree was 
perfused. The aortic arch and its main branch points were excised, fixed over­
night, and embedded in paraffin. The rest of the arterial tree was fixed, opened, 
pinned, and stained with Oil­red­O for en face analysis. Longitudinal sections 
of the aortic arch were analyzed for plaque extent and phenotype as previously 
described (Virmani et al., 2000; Lutgens et al., 2006). For phenotypic parame­
ters, immunohistochemistry was performed for CD3 (Dako), CD45 (BD), 
mac­3 (BD), FVIII (Dako), ­SMA (Sigma­Aldrich), caspase 3 (Cell Signaling 
Technology), FoxP3 (eBioscience), collagen I (Abcam), collagen III (Abcam), 
MMP­2 (Cell Signaling Technology), MMP­9 (Santa Cruz Biotechnology, 
Inc.). In addition, Perl’s iron staining and Sirius red staining were as previously 
described (Lutgens et al., 2006). Morphometric analyses were performed using 
a Quantimet (Leica) with Qwin3 software (Leica). Plasma cholesterol levels 
were measured enzymatically (Roche), organs were analyzed by hematoxylin 
and eosin staining, and no abnormalities were observed. Serum sCD40L levels 
were measured by ELISA (eBioscience).
In vitro macrophage culture. BM cells were isolated from n = 6 mice/
group and cultured in RPMI supplemented with L929 conditioned medium 
to generate BM­derived macrophages as previously described (Kanters et al., 
2003). Cells were pretreated with 100 U IFN­ for 24 h to induce MHCII 
expression and then treated for 3 h with 100 ng/ml FGK45, a CD40­stimulat­
ing antibody. Cytokine levels in the medium were measured by FACS using 
a cytometric bead assay (BD), and quantitative gene expression of cytokines, 
M1, and M2 macrophage markers were analyzed as previously described 
(Beckers et al., 2007).
Macrophage migration assay. Macrophage migration was assessed using 
24­well Transwell migration chambers (Costar; Corning) with a pore size of   
6 µm. BM­derived macrophages (0.5 × 106) of the respective genotypes, sus­
pended in serum­free medium, were added to each chamber. Complete me­
dium, including 100 ng/ml CCL2 (R&D Systems), was added to the lower 
chambers and migration was performed at 37°C for 4 h. Nonmigrated cells 
were removed from the membranes, and migrated cells within the membrane 
were fixed with methanol and stained with toluidine blue. Membranes were 
cut out of inserts and mounted onto slides in immersion oil. The number of 
migrated cells was counted on five randomly chosen fields of each membrane.
Gelatinase assay. Gelatinase activity in the supernatant of FGK45­treated 
macrophages was determined using the EnzChek gelatinase/collagenase assay 
kit (Invitrogen). Substrate hydrolysis was analyzed after 24 h at room tempera­
ture and fluorescence was detected using a fluorescence microplate reader.
Intravital microscopy. Leukocyte endothelial interactions were analyzed 
by intravital microscopy of the left carotid artery (n = 8 mice/group; Koenen 
et al., 2009). 6 h after i.p. injection of 1.0 µg of mouse TNF (PeproTech), 
mice were anaesthetized with ketamine/xylazine and the left carotid artery 
was exposed. Circulating leukocytes were labeled by i.v. injection of rhoda­
mine 6G. Ly6C+ inflammatory monocytes were labeled with fluorescent   
latex beads as previously described (Soehnlein et al., 2008). The antibody to 
IL­10 (clone JES5.2A) was injected twice i.p. (500 µg/mouse), 24 and 2 h 
before intravital microscopy. Recordings were made using a microscope 
(BX51; Olympus) equipped with a saline­immersion 20× objective.
Statistics. Data are presented as mean ± SEM. Data were analyzed by a 
nonparametric Mann­Whitney U test or Welch­corrected t test, as appropri­
ate, using Prism 4 software (GraphPad Software, Inc.). P­values <0.05 were 
considered significant.
Online supplemental material. Fig. S1 shows additional phenotypic fea­
tures of the atherosclerotic plaques of CD40/Apoe/ mice (classification 
of Virmani et al. [2000], Caspase 3 and FoxP3 levels). Fig. S2 shows MMP­2 
and MMP­9 levels in plaques of CD40/Apoe/ mice, as well as gelatinase 
activity and TIMP­1 levels in their BM­derived macrophages. Fig. S3 shows 
the extended immune phenotyping of splenocytes in all the experimental 
groups. Fig. S4 shows the balanced effector T cell phenotype in absence of 
CD40­TRAF2/3/5 interactions. Fig. S5 shows MMP­2 and MMP­9 levels 
in plaques of the CD40-TRAF mice, as well as gelatinase activity and TIMP­1 
levels in their BM­derived macrophages. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20091293/DC1.
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